All studies
Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Eip Pharma Inc.
Enrolment target
15
Start
24 Jul 2023
Subjects aged ≥55 years with probable Dementia with Lewy Bodies DLB by consensus criteria (McKeith et al2017)including a positive DaTscan™ and a CDR Global Score of 0.5 or 1.0. If the DaTscan is negativebut the subject has historical polysomnography (PSG)-verified REM sleep behavioral disorder (RBD)this will also qualify as probable DLB.
What is this study about?
Change (from Baseline to Week 16) in CDR-SB in neflamapimod treated-subjects compared to the placebo-treated subjects.
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (1)
- —Netherlands
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.